Home > News In Oncologia > Cellule tumorali circolanti e melanoma Un lavoro di S.Mocellin e coll., dell’Università di Padova, pubblicato sull’International Journal of Cancer, afferma che il riscontro di cellule tumorali circolanti, in pazienti con melanoma cutaneo, rappresenta un fattore prognostico negativo, predittivo di recidiva neoplastica.

Cellule tumorali circolanti e melanoma Un lavoro di S.Mocellin e coll., dell’Università di Padova, pubblicato sull’International Journal of Cancer, afferma che il riscontro di cellule tumorali circolanti, in pazienti con melanoma cutaneo, rappresenta un fattore prognostico negativo, predittivo di recidiva neoplastica.

Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma.

Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, Pilati P, Nitti D, Lise M, Rossi CR.

Department of Oncologic and Surgical Sciences, University of Padua, Padua, Italy.

Detection of circulating tumor cells (CTCs) might improve current staging procedures by identifying a subgroup of patients with minimal residual disease and thus a higher risk of disease recurrence. Forty patients with > or =2-mm-thick cutaneous melanoma with or without lymph node metastasis were enrolled. After standard radical surgery and adjuvant therapy in case of lymph node metastasis, patients were followed up with routine physical and radiologic assessments as well as serial PCR-based analysis of CTCs using 2 melanoma markers (tyrosinase and Melan-A/Mart-1). After a median follow-up of 30 months, 18 patients had disease recurrence and 28 were PCR-positive before the disease became clinically evident. The sensitivity of the molecular test was 83%. Median time to PCR positivity and median PCR-to-relapse time were 12 and 8 months, respectively. At multivariate analysis, PCR positivity was an independent predictor of disease recurrence (hazard ratio=2.06, 95% CI 1.07-3.35; p=0.03). Among high-risk melanoma patients, serial PCR-based analysis of CTCs can identify a subgroup at higher risk of disease recurrence, with clinically significant advance. Therefore, CTC detection might be employed for the selection of patients for adjuvant treatment and during follow-up for early indication of therapeutic failure. Copyright 2004 Wiley-Liss, Inc.

Categorie:News In Oncologia Tag:
  1. Non c'è ancora nessun commento.
  1. No trackbacks yet.

Lascia un commento

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione / Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione / Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione / Modifica )

Google+ photo

Stai commentando usando il tuo account Google+. Chiudi sessione / Modifica )

Connessione a %s...

%d blogger cliccano Mi Piace per questo: